Skip to main content
Erschienen in: Supportive Care in Cancer 2/2010

01.02.2010 | Original Article

The life-sustaining treatments among cancer patients at end of life and the caregiver’s experience and perspectives

verfasst von: Young Ho Yun, Myung Kyung Lee, Yoon Jung Chang, Chang Hoon You, Samyong Kim, Jong Soo Choi, Ho-Yeong Lim, Chang Geol Lee, Youn Seon Choi, Young Seon Hong, Si-Young Kim, Dae Seog Heo, Hyun Sik Jeong

Erschienen in: Supportive Care in Cancer | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Goals of work

The goal of this study was to investigate the utilization of and attitudes toward life-sustaining treatments (LSTs) at the end of life.

Materials and methods

We identified 4,042 families of cancer patients who had died at any of 17 hospitals in Korea during 2004. Among those, we analyzed the interviews provided by 1,592 (39.4%) primary caregivers. Only women who provided information in baseline and follow-up point could be included for internal comparison.

Main results

Most caregivers did not discuss with their patient the option of utilizing the intensive care unit (ICU; 92.7%) or cardiopulmonary resuscitation (CPR; 93.7%) to prolong an ending life. Logistic regressions indicated that the ICU was more likely to be utilized when patients experienced an unexpected medical problem before dying, discussed the ICU with the family caregiver, or were low-educated. CPR was more likely to be used if the patient died within 6 months of diagnosis or the family caregiver was <65 years old. Family caregivers more likely to use the ICU if placed in the same situation again were those whose patients had a higher monthly income or died within 6 months of diagnosis, low-educated, or had utilized the ICU.

Conclusions

Our findings underscore the importance of discussing LST with terminally ill patients based on adequate information.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Lynn J, Teno JM, Phillips RS et al (1997) Perceptions by family members of the dying experience of older and seriously ill patients. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Ann Intern Med 126:97–106PubMed Lynn J, Teno JM, Phillips RS et al (1997) Perceptions by family members of the dying experience of older and seriously ill patients. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Ann Intern Med 126:97–106PubMed
9.
Zurück zum Zitat Diamond EL, Jernigan JA, Moseley RA et al (1989) Decision-making ability and advance directive preferences in nursing home patients and proxies. Gerontologist 29:622–626PubMed Diamond EL, Jernigan JA, Moseley RA et al (1989) Decision-making ability and advance directive preferences in nursing home patients and proxies. Gerontologist 29:622–626PubMed
13.
Zurück zum Zitat Sulmasy DP, Terry PB, Weisman CS et al (1998) The accuracy of substituted judgments in patients with terminal diagnoses. Ann Intern Med 128:621–629PubMed Sulmasy DP, Terry PB, Weisman CS et al (1998) The accuracy of substituted judgments in patients with terminal diagnoses. Ann Intern Med 128:621–629PubMed
17.
Zurück zum Zitat Yun YH et al (2004) Public attitudes toward dying with dignity and hospice·palliative care. Korean J of Hospice and Palliative Care 7(1):17–28 Yun YH et al (2004) Public attitudes toward dying with dignity and hospice·palliative care. Korean J of Hospice and Palliative Care 7(1):17–28
21.
Zurück zum Zitat Hui E, Ho SC, Tsang J et al (1997) Attitudes toward life-sustaining treatment of older persons in Hong Kong. J Am Geriatr Soc 45:1232–1236PubMed Hui E, Ho SC, Tsang J et al (1997) Attitudes toward life-sustaining treatment of older persons in Hong Kong. J Am Geriatr Soc 45:1232–1236PubMed
23.
Zurück zum Zitat Lurie N, Pheley AM, Miles SH et al (1992) Attitudes toward discussing life-sustaining treatments in extended care facility patients. J Am Geriatr Soc 40:1205–1208PubMed Lurie N, Pheley AM, Miles SH et al (1992) Attitudes toward discussing life-sustaining treatments in extended care facility patients. J Am Geriatr Soc 40:1205–1208PubMed
26.
Zurück zum Zitat Hilfiker D (1983) Sounding Board. Allowing the debilitated to die. Facing our ethical choices. N Engl J Med 308:716–719PubMedCrossRef Hilfiker D (1983) Sounding Board. Allowing the debilitated to die. Facing our ethical choices. N Engl J Med 308:716–719PubMedCrossRef
27.
Zurück zum Zitat McCormick TR, Conley BJ (1995) Patients’ perspectives on dying and on the care of dying patients. West J Med 163:236–243PubMed McCormick TR, Conley BJ (1995) Patients’ perspectives on dying and on the care of dying patients. West J Med 163:236–243PubMed
Metadaten
Titel
The life-sustaining treatments among cancer patients at end of life and the caregiver’s experience and perspectives
verfasst von
Young Ho Yun
Myung Kyung Lee
Yoon Jung Chang
Chang Hoon You
Samyong Kim
Jong Soo Choi
Ho-Yeong Lim
Chang Geol Lee
Youn Seon Choi
Young Seon Hong
Si-Young Kim
Dae Seog Heo
Hyun Sik Jeong
Publikationsdatum
01.02.2010
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 2/2010
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-009-0644-0

Weitere Artikel der Ausgabe 2/2010

Supportive Care in Cancer 2/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.